


- DNDI-6148 is a potential drug for treatment of leishmaniasis, a disease caused by the protozoa parasite *Leishmania*.
- Currently in clinical phase I trial.

Chatelain, E.; Ioset, J.-R. *DDDT* **2011**, *5*, 175–181. <https://doi.org/10.2147/DDDT.S16381>.

Letavic, M. A.; Bonaventure, P.; Carruthers, N. I.; Dugovic, C.; Koudriakova, T.; Lord, B.; Lovenberg, T. W.; Ly, K. S.; Mani, N. S.; Mowbray, C. E.; Brailard, S.; Glossop, P. A.; Whitlock, G. A.; Jacobs, R. T.; Speake, J.; Pandi, B.; Nare, B.; Maes, L.; Yardley, V.; Freund, Y.; Wall, R. J.; Carvalho, S.; Bello, D.; Van den Kerkhof, M.; Caljon, G.; Gilbert, I. H.; Corpas-Lopez, V.; Lukac, I.; Patterson, S.; Zuccotto, F.; Wyllie, S. *J. Med. Chem.* **2021**, *64*, 16159–16176. <https://doi.org/10.1021/acs.jmedchem.1c01437>.

Khairnar, P. V.; Saathoff, J. M.; Cook, D. W.; Hochstetler, S. R.; Pandya, U.; Robinson, S. J.; Satam, V.; Donsbach, K. O.; Gupton, B. F.; Jin, L.-M.; Shanahan, C. S. *Org. Process Res. Dev.* **2024**, *28*, 1213–1223. <https://doi.org/10.1021/acs.oprd.4c00031>.


Initial route



Cat. No.: A616316


2D

3D




Purity	Size	Price
98%	250mg	\$9.00
98%	1g	\$14.00
98%	5g	\$30.00
98%	10g	\$37.00
98%	25g	\$47.00
98%	100g	\$187.00

Design of new routes



Optimized route I



- Decagram synthesis achieved
- Column (step1) and reverse phase (step 5) required

Optimized route II

